Bray F, Laversanne M, Sung HYA, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Li Y, Jiang ML, Aye L, Luo L, Zhang Y, Xu FK, et al. UPP1 promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment. Nat Commun. 2024;15:1200.

Article  PubMed  PubMed Central  Google Scholar 

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.

Article  CAS  PubMed  Google Scholar 

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, et al. EAdjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017;35:2960.

Article  PubMed  Google Scholar 

Guo HY, Zhang J, Qin C, Yan H, Luo XY, Zhou HN. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review. Medicine. 2024;103:e36861.

Article  PubMed  PubMed Central  Google Scholar 

Guo ZW, Wei X, Tang CH, Liang J. Non-tumor-related prognostic factors for immunotherapy-chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC). Clin Exp Med. 2024;24:52.

Article  PubMed  PubMed Central  Google Scholar 

Naschitz JE. Cancer-Associated Atherothrombosis: The Challenge. Int J Angiol. 2021;30:249–56.

Article  PubMed  PubMed Central  Google Scholar 

Falanga A, Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J Thromb Haemost. 2023;21:1397–408.

Article  PubMed  Google Scholar 

Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712–23.

Article  CAS  PubMed  Google Scholar 

Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects. J Thromb Haemost. 2013;11:223–33.

Article  CAS  PubMed  Google Scholar 

Beleva EA, Deneva T, Stoencheva S, Popov V, Grudeva-Popova Z. Hemostatic Biomarkers Based Predictive Model for Metastatic Disease, Progression and Mortality in Cancer Patients. Haematologica. 2016;101:142–142.

Google Scholar 

Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res. 2018;164:S54–S61.

Article  CAS  PubMed  Google Scholar 

Vanrusselt D, Sleurs C, Arif M, Lemiere J, Verschueren S, Uyttebroeck A. Biomarkers of fatigue in oncology: A systematic review. Crit Rev Oncol Hemat. 2024;194:104245.

Article  Google Scholar 

Hu HY, Song HQ, Han B, Zhao HL, He JF. Tumor-Educated Platelet RNA and Circulating Free RNA: Emerging Liquid Biopsy Markers for Different Tumor Types. Front Biosci-Landmrk. 2024;29:80.

Article  Google Scholar 

Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. Ejso-Eur J Surg Onc. 2013;39:951–6.

Article  CAS  Google Scholar 

Saidak Z, Soudet S, Lottin M, Salle V, Sevestre MA, Clatot F, et al. A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. Cancer Immunol Immun. 2021;70:923–33.

Article  CAS  Google Scholar 

Marchetti M, Falanga A. Hemostatic biomarkers in occult cancer and cancer risk prediction. Thromb Res. 2020;191:S37–S42.

Article  CAS  PubMed  Google Scholar 

Varkey J, Nicolaides T. Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors. Cureus. J Med Sci. 2021;13:e19189.

Google Scholar 

Adams GN, Rosenfeldt L, Frederick M, Miller W, Waltz D, Kombrinck K, et al. Colon Cancer Growth and Dissemination Relies upon Thrombin, Stromal PAR-1, and Fibrinogen. Cancer Res. 2015;75:4235–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimoda M. Modulation of tissue microenvironmental factors in tumor progression. Cancer Sci. 2023;114:921–921.

Google Scholar 

Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis. Semin Thromb Hemost. 2019;45:396–412.

Article  CAS  PubMed  Google Scholar 

Tang LA, Liu K, Wang JF, Wang C, Zhao P, Liu JZ. High Preoperative Plasma Fibrinogen Levels Are Associated With Distant Metastases and Impaired Prognosis After Curative Resection in Patients With Colorectal Cancer. J Surg Oncol. 2010;102:428–32.

Article  PubMed  Google Scholar 

Zhao B, Zhang YL, Huang YN, Yu JC, Li YR, Wang Q, et al. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection. Thromb Haemostasis. 2017;117:44–56.

Article  Google Scholar 

Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605–12.

Article  CAS  PubMed  Google Scholar 

Xue YH, Zhang XF, Dong QZ, Sun JA, Dai C, Zhou HJ, et al. Thrombin is a Therapeutic Target for Metastatic Osteopontin-Positive Hepatocellular Carcinoma. Hepatology. 2010;52:2012–22.

Article  CAS  PubMed  Google Scholar 

Zhao B, Wu MF, Hu ZH, Ma YX, Qi W, Zhang YL, et al. Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation. Signal Transduct Tar. 2020;5:1556–67.

Google Scholar 

Reddel CJ, Allen JD, Ehteda A, Taylor R, Chen VMY, Curnow JL, et al. Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. J Thromb Haemost. 2017;15:477–86.

Article  CAS  PubMed  Google Scholar 

Leung LL, Myles T, Morser J. Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response. Cancers. 2023;15:3480.

Article  PubMed  PubMed Central  Google Scholar 

Baumdick M, Gelléri M, Uttamapinant C, Beránek V, Chin JW, Bastiaens PIH. A conformational sensor based on genetic code expansion reveals an autocatalytic component in EGFR activation. Nat Commun. 2018;9:3847.

Article  PubMed  PubMed Central  Google Scholar 

Lee JH, Liu R, Li J, Wang YG, Tan L, Li XJ, et al. EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. Mol Cell. 2018;70:197.

Article  PubMed  PubMed Central  Google Scholar 

Law NC, White MF, Hunzicker-Dunn ME. G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway. J Biol Chem. 2016;291:27160–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Tar. 2021;6:425.

Article  Google Scholar 

Lyu H, Han A, Polsdofer E, Liu S, Liu BL. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 2018;8:503–10.

Article  PubMed  PubMed Central  Google Scholar 

Remon J, Saw SPL, Cortiula F, Singh PK, Menis J, Mountzios G, et al. Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges. J Thorac Oncol. 2024;19:199–215.

Article  CAS  PubMed  Google Scholar 

Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007;67:4425–33.

Article  CAS